Deuterated colexitinib (decavatinib) approved indications and latest guidelines

Deucravacitinib is a new oral TYK2 inhibitor that is currently approved for the treatment of moderate to severe plaque psoriasis in adults. This drug is suitable for patients whose conventional topical drugs or phototherapy are unsatisfactory and whose disease persists or progresses. By targeting the TYK2 signaling pathway, decavatinib can effectively regulate the activity of pro-inflammatory cytokines in the body, including IL‑12, IL‑23 and I type interferons, thereby improving the skin symptoms and inflammatory response of psoriasis. Compared with injectable biologics, its oral administration method is more convenient for patients to use for a long time and improves compliance.

In the latest clinical guidelines, decavatinib is clearly recommended as an important systemic treatment option for patients with moderate to severe plaque psoriasis, especially for patients who wish to avoid strong immunosuppression or injectable drugs. The guideline states that the drug can be used alone or in combination with other non-immunosuppressive therapies in certain circumstances to enhance efficacy or improve patients' quality of life. During use, doctors need to evaluate the patient's basic health status, especially infection history and immune function, to ensure safety.

Key Phase III clinical trial data show that patients taking 6 mg decavatinib daily reached 16 weeks. PASI‑75 (Psoriasis Area and Severity Index improvement ≥75%) was significantly higher than that in the placebo group, and the efficacy remained stable during long-term follow-up. At the same time, the drug has a low incidence of adverse reactions, mostly mild to moderate, including upper respiratory tract infection, headache and mild diarrhea, suggesting that it is well tolerated and suitable for long-term maintenance treatment.

Clinical practice shows that the use of decavatinib can significantly improve the skin symptoms, itching and quality of life of patients with psoriasis, while reducing the risk of disease recurrence. Doctors should regularly monitor patient efficacy and safety indicators during medication, and adjust dosage or treatment plans based on clinical responses. For special groups, such as patients with hepatic and renal insufficiency or chronic infection, the risk should be carefully assessed before deciding whether to use it. Overall, deuterated colexitinib provides a new oral, safe and stable systemic treatment option for patients with moderate to severe psoriasis.

Reference materials:https://www.ema.europa.eu/en/homepage